Recombinant Human MAD2L1 Protein，His

MAD2L1 (MITOTIC ARREST DEFICIENT 2-LIKE 1) is a crucial protein that plays a vital role in the spindle assembly checkpoint (SAC), a mechanism that ensures proper chromosome segregation during cell division. Dysfunction or dysregulation of MAD2L1 has been implicated in various cancers, as it can lead to aneuploidy, a condition characterized by an abnormal number of chromosomes. The study of recombinant MAD2L1 protein has gained increasing attention in the field of cancer biology and therapy, as understanding its structure and function could provide insights into its role in SAC and cellular proliferation. Researchers have focused on producing recombinant MAD2L1 to investigate its interactions with other checkpoint proteins, such as CDC20 and APC/C, and to explore its potential as a target for cancer therapeutics. By elucidating the molecular mechanisms underlying MAD2L1 function, scientists aim to identify novel strategies for restoring proper cell cycle regulation in tumor cells, enhancing the efficacy of existing treatments, and potentially developing new anti-cancer agents. Furthermore, structural studies of recombinant MAD2L1 using techniques such as X-ray crystallography and NMR spectroscopy offer valuable information about its conformational states and binding dynamics, paving the way for the design of small molecules that can modulate its activity. Overall, research on recombinant MAD2L1 not only enhances our basic understanding of mitotic checkpoints but also holds therapeutic promise for improving cancer treatment outcomes.